REKinDLE: Registry With Enbrel® or Kineret® in a Database Using Longitudinal Evaluations
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if Enbrel® or Kineret® will have a positive effect
on subject functionality as measured by the Health Assessment Questionnaire Disability Index
(HAQDI).
Details
Lead Sponsor:
Amgen
Treatments:
Etanercept Interleukin 1 Receptor Antagonist Protein